文献速递细菌感染、耐药与抗菌药物

法定制剂噬菌体制剂:这是所有人的模式吗?

Magistral Phage Preparations: Is This the Model for Everyone?
PubMed 文献 · Clin Infect Dis · 2023-01-01

噬菌体疗法被视为应对全球抗菌药物耐药危机的有前景的附加工具,但工业化生产的噬菌体药品目前未在欧盟和美国上市。作者认为,由医院和学术机构通过法定制剂方式个性化制备噬菌体制剂可提供即时解决方案,并补充未来工业化产品,但需建立务实且分层的质量与安全保证要求。

要点

  • 工业化噬菌体药品未在欧盟和美国上市,未来产品可能主要针对商业可行菌种和适应症。
  • 作者认为医院和学术机构法定制剂个性化噬菌体产品可提供即时解决方案。
  • 作者认为此类制剂可能比固定噬菌体鸡尾酒更有效且细菌噬菌体耐药问题更少,但需科学证实。

核心结论

  • 作者认为,基于医院和学术机构法定制剂个性化噬菌体产品的国家方案可提供即时解决方案,并补充未来工业化产品。

研究设计与样本

  • 本文为观点文章,讨论噬菌体疗法的监管与制备模式,未报告系统检索或样本量。

主要发现

  • 工业化生产的噬菌体药品目前未在欧盟和美国市场上市。
  • 未来以商业为目的的噬菌体产品预计主要针对商业可行的细菌种类和临床适应症,并使用固定噬菌体鸡尾酒。
  • 作者认为,法定制剂个性化噬菌体产品可能比固定噬菌体鸡尾酒更有效且引起较少细菌噬菌体耐药问题,但该主张需尽快得到科学证实。

关键数值与推荐

  • 作者认为,应为此类个性化噬菌体产品的现有生产者提供务实且最好至少在欧洲层面标准化的质量与安全保证要求,并基于个体患者层面的获益-风险评估进行分层。
  • 作者认为,不应以药品生产质量管理规范等行业标准要求来阻止无偿提供噬菌体疗法的提供者。

临床怎么用

  • 作者建议,像比利时一样,其他欧洲国家可建立法定噬菌体制剂框架,与常规药品开发和许可途径并存。
  • 作者认为,医院或噬菌体治疗中心急需 adequate 噬菌体制剂以帮助所有难治性感染患者。

局限性

  • 作者提出,法定制剂个性化噬菌体产品比固定噬菌体鸡尾酒更有效且引起较少细菌噬菌体耐药问题的主张需要尽快得到科学证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phage therapy is increasingly put forward as a promising additional tool to help curb the global antimicrobial resistance crisis. However, industrially manufactured phage medicinal products are currently not available on the European Union and United States markets. In addition, it is expected that the business purpose-driven phage products that are supposed to be marketed in the future would mainly target commercially viable bacterial species and clinical indications, using fixed phage cocktails. hospitals or phage therapy centers aiming to help all patients with difficult-to-treat infections urgently need adequate phage preparations. We believe that national solutions based on the magistral preparation of personalized (preadapted) phage products by hospital and academic facilities could bring an immediate solution and could complement future industrially manufactured products. Moreover, these unlicensed phage preparations are presumed to be more efficient and to elicit less bacterial phage resistance issues than fixed phage cocktails, claims that need to be scientifically substantiated as soon as possible. Just like Belgium, other (European) countries could develop a magistral phage preparation framework that would exist next to the conventional medicinal product development and licensing pathways. However, it is important that the current producers of personalized phage products are provided with pragmatic quality and safety assurance requirements, which are preferably standardized (at least at the European level), and are tiered based on benefit-risk assessments at the individual patient level. Pro bono phage therapy providers should be supported and not stopped by the imposition of industry standards such as Good Manufacturing Practice requirements. Keywords: antimicrobial resistance; antibiotic resistance; bacterial infection; bacteriophage therapy; magistral preparation.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Pirnay JP, Verbeken G. Magistral Phage Preparations: Is This the Model for Everyone? Clin Infect Dis. 2023. PMID: 37932120. doi:10.1093/cid/ciad481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。